Current concepts and controversies in the treatment of alcoholic hepatitis

Table 4 Infliximab trials in the treatment of alcoholic hepatitis

Study	Design	Patients	Treatment	Results
Spahr et al[76]	Randomized	20	All patients: prednisone for 28 d	Improved Maddrey score
2002			Randomized d 0	No significant difference in survival, histology or adverse outcomes
			R1: Infliximab 5 mg/kg
			R2: Placebo
Tilg et al[77]	Case Series	12	Infliximab 5 mg/kg	83% (10/12) survived at median 15 mo
2003				No mention of infection
Mookerjee et al[78]	Case Series	10	Infliximab 5 mg/kg times one	72 h assessment
2003				Significant reduction in laboratory parameters
				Increased hepatic and renal blood flow
Naveau et al[79]	Randomized	36	All patients: Prednisone for 28 d	Significantly higher rate of infections in treated group
2004			R1: Infliximab 10 mg/kg	Non-significantly higher rate of death in treated group
			R2: Placebo	Study stopped secondary to adverse events in treatment group